Nogapendekin alfa inbakicept (1) – Anktiva®
BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC), in combination with Bacillus Calmette-Guérin (BCG)
Characteristics
| Start date | 15.09.2026 |
|---|---|
| Resolution | 04.03.2027 – active procedure |
| INN | Nogapendekin alfa inbakicept |
| Brand name | Anktiva® |
| Pharm. company | ImmunityBio, Inc. |
| G-BA Procedure ID | D-1376 |
| Therapeutic area | Oncological diseases |
| Reason for procedure | Initial assessment |
Associated procedures
<< List of all resolutions